Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director · Bd. Co-Chair, President & CSO | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 310,460 |
Ending reported balance
After 2025-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-31 · Exercise / conversion · Acquired 28,570 · Balance 339,030 Row 2 · 2025-12-31 · Tax withholding · Disposed 28,570 · Balance 310,460 |
| 2020 Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 595,077 |
Reported balance
After 2025-12-31 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-12-31 · Exercise / conversion · Disposed 28,570 · Balance 595,077 F2: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. |
| Common StockSEC Table I · non-derivative | IndirectBy 2024 GRAT | 71,487 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 71,487 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 200,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 200,000 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT II | 200,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 200,000 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,962 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,962 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust for Chldn. | 180,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 180,000 F1: As investment trustee of trusts for the benefit of the reporting person's children. |
| Common StockSEC Table I · non-derivative | Indirectby 2024 GRAT II | 101,988 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 101,988 |
| Common StockSEC Table I · non-derivative | Indirectby Children | 56,048 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 56,048 |
Filing footnotes · ownership attribution and instrument terms
F1: As investment trustee of trusts for the benefit of the reporting person's children.
F2: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2025 Filed Jan 5, 2026 22:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversion2020 Performance Stock Units · Derivative | 28,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001226690-26-000002 · edgardoc.xml · derivative · entry 10 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 595,077 Underlying: Common Stock · 28,570 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. F2 · derivative.exercise_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. F2 · derivative.expiration_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 28,570 | $772.09 | $22,058,611.30 |
DisclosureSEC source: 0001226690-26-000002 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,460 Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 28,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001226690-26-000002 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 146,815 | $0.00 Strike: $555.67 | $0.00 |
DisclosureSEC source: 0001226690-25-000005 · edgardoc.xml · derivative · entry 10 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 146,815 shares Expires 2025-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 131,874 | $701.51 | $92,510,929.74 |
DisclosureSEC source: 0001226690-25-000005 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,460 Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 146,815 | $555.67 | $81,580,691.05 |
DisclosureSEC source: 0001226690-25-000005 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 442,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 37,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-24-000033 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Indirect · by Children Disclosed balance after: 56,048 Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 75,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-24-000033 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Indirect · by 2022 GRAT II Disclosed balance after: 0 Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 379 | $978.18 | $370,730.22 |
DisclosureSEC source: 0001968202-24-000094 · edgardoc.xml · nonDerivative · entry 12 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 786,383 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F13 · price: Represents volume-weighted average price of sales of 379 shares of Company stock on May 16, 2024 at prices ranging from $978.07 to $978.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,227 | $977.38 | $1,199,245.26 |
DisclosureSEC source: 0001968202-24-000094 · edgardoc.xml · nonDerivative · entry 11 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 786,762 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F12 · price: Represents volume-weighted average price of sales of 1,227 shares of Company stock on May 16, 2024 at prices ranging from $977.02 to $977.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,886 | $976.52 | $4,771,276.72 |
DisclosureSEC source: 0001968202-24-000094 · edgardoc.xml · nonDerivative · entry 10 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 787,989 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F11 · price: Represents volume-weighted average price of sales of 4,886 shares of Company stock on May 16, 2024 at prices ranging from $976.00 to $976.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9,242 | $975.48 | $9,015,386.16 |
DisclosureSEC source: 0001968202-24-000094 · edgardoc.xml · nonDerivative · entry 9 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 792,875 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F10 · price: Represents volume-weighted average price of sales of 9,242 shares of Company stock on May 16, 2024 at prices ranging from $975.00 to $975.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,611 | $974.51 | $7,416,995.61 |
DisclosureSEC source: 0001968202-24-000094 · edgardoc.xml · nonDerivative · entry 8 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 802,117 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F9 · price: Represents volume-weighted average price of sales of 7,611 shares of Company stock on May 16, 2024 at prices ranging from $974.00 to $974.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,653 | $973.80 | $2,583,491.40 |
DisclosureSEC source: 0001968202-24-000094 · edgardoc.xml · nonDerivative · entry 7 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 809,728 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F8 · price: Represents volume-weighted average price of sales of 2,653 shares of Company stock on May 16, 2024 at prices ranging from $973.20 to $973.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 790 | $972.22 | $768,053.80 |
DisclosureSEC source: 0001968202-24-000094 · edgardoc.xml · nonDerivative · entry 6 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 812,381 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F7 · price: Represents volume-weighted average price of sales of 790 shares of Company stock on May 16, 2024 at prices ranging from $972.00 to $972.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,922 | $971.56 | $4,782,018.32 |
DisclosureSEC source: 0001968202-24-000094 · edgardoc.xml · nonDerivative · entry 5 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 813,171 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F6 · price: Represents volume-weighted average price of sales of 4,922 shares of Company stock on May 16, 2024 at prices ranging from $971.05 to $971.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,669 | $970.26 | $4,530,143.94 |
DisclosureSEC source: 0001968202-24-000094 · edgardoc.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 818,093 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F5 · price: Represents volume-weighted average price of sales of 4,669 shares of Company stock on May 16, 2024 at prices ranging from $970.00 to $970.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9,501 | $969.39 | $9,210,174.39 |
DisclosureSEC source: 0001968202-24-000094 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 822,762 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F4 · price: Represents volume-weighted average price of sales of 9,501 shares of Company stock on May 16, 2024 at prices ranging from $969.03 to $969.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,213 | $968.44 | $3,111,597.72 |
DisclosureSEC source: 0001968202-24-000094 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 832,263 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F3 · price: Represents volume-weighted average price of sales of 3,213 shares of Company stock on May 16, 2024 at prices ranging from $968.04 to $968.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 907 | $967.40 | $877,431.80 |
DisclosureSEC source: 0001968202-24-000094 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 835,476 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F2 · price: Represents volume-weighted average price of sales of 907 shares of Company stock on May 16, 2024 at prices ranging from $967.13 to $967.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 16, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 120 | $989.14 | $118,696.80 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 25 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 836,383 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F25 · price: Represents volume-weighted average price of sales of 120 shares of Company stock on May 15, 2024 at prices ranging from $989.01 to $989.28. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 373 | $988.36 | $368,658.28 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 24 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 836,503 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F24 · price: Represents volume-weighted average price of sales of 373 shares of Company stock on May 15, 2024 at prices ranging from $988.00 to $988.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 182 | $987.38 | $179,703.16 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 23 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 836,876 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F23 · price: Represents volume-weighted average price of sales of 182 shares of Company stock on May 15, 2024 at prices ranging from $987.03 to $987.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 442 | $986.40 | $435,988.80 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 22 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 837,058 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F22 · price: Represents volume-weighted average price of sales of 442 shares of Company stock on May 15, 2024 at prices ranging from $986.30 to $986.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 647 | $985.62 | $637,696.14 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 21 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 837,500 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F21 · price: Represents volume-weighted average price of sales of 647 shares of Company stock on May 15, 2024 at prices ranging from $985.11 to $985.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 53 | $984.02 | $52,153.06 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 20 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 838,147 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 727 | $983.88 | $715,280.76 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 19 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 838,200 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F20 · price: Represents volume-weighted average price of sales of 727 shares of Company stock on May 15, 2024 at prices ranging from $983.21 to $983.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 303 | $982.29 | $297,633.87 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 18 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 838,927 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F19 · price: Represents volume-weighted average price of sales of 303 shares of Company stock on May 15, 2024 at prices ranging from $982.00 to $982.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,283 | $981.52 | $2,240,810.16 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 17 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 839,230 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F18 · price: Represents volume-weighted average price of sales of 2,283 shares of Company stock on May 15, 2024 at prices ranging from $981.06 to $981.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,223 | $980.72 | $1,199,420.56 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 16 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 841,513 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F17 · price: Represents volume-weighted average price of sales of 1,223 shares of Company stock on May 15, 2024 at prices ranging from $980.11 to $980.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 504 | $979.87 | $493,854.48 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 15 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 842,736 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F16 · price: Represents volume-weighted average price of sales of 504 shares of Company stock on May 15, 2024 at prices ranging from $979.18 to $979.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,865 | $978.44 | $4,760,110.60 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 14 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 843,240 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F15 · price: Represents volume-weighted average price of sales of 4,865 shares of Company stock on May 15, 2024 at prices ranging from $978.01 to $978.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9,851 | $977.42 | $9,628,564.42 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 13 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 848,105 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F14 · price: Represents volume-weighted average price of sales of 9,851 shares of Company stock on May 15, 2024 at prices ranging from $977.00 to $977.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6,885 | $976.56 | $6,723,615.60 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 12 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 857,956 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F13 · price: Represents volume-weighted average price of sales of 6,885 shares of Company stock on May 15, 2024 at prices ranging from $976.00 to $976.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,225 | $975.60 | $5,097,510.00 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 11 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 864,841 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F12 · price: Represents volume-weighted average price of sales of 5,225 shares of Company stock on May 15, 2024 at prices ranging from $975.05 to $975.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,778 | $974.47 | $4,656,017.66 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 10 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 870,066 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F11 · price: Represents volume-weighted average price of sales of 4,778 shares of Company stock on May 15, 2024 at prices ranging from $974.01 to $974.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,865 | $973.43 | $1,815,446.95 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 9 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 874,844 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F10 · price: Represents volume-weighted average price of sales of 1,865 shares of Company stock on May 15, 2024 at prices ranging from $973.00 to $973.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 784 | $972.50 | $762,440.00 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 8 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 876,709 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F9 · price: Represents volume-weighted average price of sales of 784 shares of Company stock on May 15, 2024 at prices ranging from $972.05 to $972.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 406 | $971.28 | $394,339.68 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 7 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 877,493 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F8 · price: Represents volume-weighted average price of sales of 406 shares of Company stock on May 15, 2024 at prices ranging from $971.02 to $971.37. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 846 | $970.36 | $820,924.56 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 6 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 877,899 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F7 · price: Represents volume-weighted average price of sales of 846 shares of Company stock on May 15, 2024 at prices ranging from $970.26 to $970.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,930 | $969.14 | $1,870,440.20 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 5 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 878,745 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F6 · price: Represents volume-weighted average price of sales of 1,930 shares of Company stock on May 15, 2024 at prices ranging from $969.03 to $969.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,387 | $968.43 | $3,280,072.41 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 880,675 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F5 · price: Represents volume-weighted average price of sales of 3,387 shares of Company stock on May 15, 2024 at prices ranging from $968.06 to $968.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,428 | $967.45 | $1,381,518.60 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 884,062 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F4 · price: Represents volume-weighted average price of sales of 1,428 shares of Company stock on May 15, 2024 at prices ranging from $967.07 to $967.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 782 | $966.29 | $755,638.78 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 885,490 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F3 · price: Represents volume-weighted average price of sales of 782 shares of Company stock on May 15, 2024 at prices ranging from $966.04 to $966.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 111 | $965.69 | $107,191.59 |
DisclosureSEC source: 0001968202-24-000093 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 886,272 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on February 14, 2024. F2 · price: Represents volume-weighted average price of sales of 111 shares of Company stock on May 15, 2024 at prices ranging from $965.58 to $965.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| April 29, 2024 Filed May 1, 2024 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 18,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-24-000013 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Indirect · by Children Disclosed balance after: 18,148 Read SEC document |
| April 29, 2024 Filed May 1, 2024 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 36,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-24-000013 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Indirect · by 2022 GRAT I Disclosed balance after: 0 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 172,723 | $0.00 Strike: $399.66 | $0.00 |
DisclosureSEC source: 0001968202-24-000068 · edgardoc.xml · derivative · entry 7 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 172,723 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 123,601 | $953.83 | $117,894,341.83 |
DisclosureSEC source: 0001968202-24-000068 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 801,608 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 172,723 | $399.66 | $69,030,474.18 |
DisclosureSEC source: 0001968202-24-000068 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 925,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.